Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Inclusion Criteria

• •Each potential patient must satisfy all of the following criteria to be enrolled in the study:
• •Age, Type of Patient, Disease Characteristics
• •1. Male or female patients must be at least 18 years of age at the time of consent younger than 66 years.
• •2. Documented multiple myeloma satisfying the calcium elevation, renal insufficiency, anemia, and bone lesions (CRAB) criteria and measurable disease (Source: Rajkumar 2014)
• •3. Newly diagnosed patients eligible for high dose therapy and autologous Stem cell therapy.
• •4. Have a Karnofsky performance status score ≥50% (Eastern Cooperative Oncology Group ECOG performance status ECOG score ≤2.
• •5. Have clinical laboratory values meeting the following criteria.
• •Sex and Contraceptive/Barrier Requirements
• •6. A female patient of childbearing potential must have a negative serum pregnancy test within 10 to 14 days prior to the start of study treatment and again either a serum or urine pregnancy test within 24 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study and for a period of 6 months after the last dose of study treatments.
• •7. A female patient must be :
• +57 more criteria